Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Metastatic Gastric/GEJ Cancer
NCT00054457Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2003
- Primary completion
- Feb 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Sep 2003; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00054457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054457.